Election 2024How We SurviveOffice PoliticsI've Always Wondered ...My Economy

Loading...

0:00
0% played
Stories Tagged as

Valeant

Why Bill Ackman sees activist investing as a moral crusade

by Kai Ryssdal , Bridget Bodnar and Sean McHenry
Oct 31, 2017
For the Pershing Square Capital Management CEO, activist investing is just as much a moral calling as it is a lucrative one
Bill Ackman attends the Hamptons International Film Festival SummerDocs Series screening of 'Betting On Zero' at Guild Hall on August 6, 2016 in East Hampton, New York.
Matthew Eisman/Getty Images for Hamptons International Film Festival
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Valeant Pharmaceuticals and the dark side of capitalism

by Kai Ryssdal
Jun 10, 2016
Investors' demands for more profits left patients with the choice to pay up or die.
Howard Schiller, interim CEO of Valeant Pharmaceuticals International, and Nancy Retzlaff, chief commercial officer for Turing Pharmaceuticals, listen during a hearing of the House Oversight and Government Reform Committee on Capitol Hill February 4, 2016 in Washington, DC.
BRENDAN SMIALOWSKI/AFP/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

How to oust a corporate board member

by Tracey Samuelson
Mar 24, 2016
Toppling Yahoo's entire board or removing one Valeant board member can be hard.
Yahoo CEO Marissa Mayer is facing pressure after a letter was sent to Yahoo's shareholders suggesting that the board and CEO should be replaced. 
Stephen Lam/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Valeant's story: a cautionary tale

by Dan Gorenstein
Mar 21, 2016
The company's CEO stepped down on Monday
Howard Schiller, then interim CEO of Valeant Pharmaceuticals International, Inc., listens during a hearing of the House Oversight and Government Reform Committee on Capitol Hill February 4, 2016 in Washington, DC. 
BRENDAN SMIALOWSKI/AFP/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Valeant swears off aggressive drug pricing strategy

by Dan Gorenstein
Mar 15, 2016
Valeant and a handful other firms may ditch a model that's come under fire.
Valeant and a handful other firms may ditch a model that's come under fire.
Image via Life Science Association of Manitoba/YouTube
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Valeant: how aggressively can a drug company sell

by Mitchell Hartman
Oct 30, 2015
Valeant is under scrutiny for its business practices.
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Why drugmakers are suddenly merging

by Dan Gorenstein
Aug 20, 2015
Valeant Pharmaceuticals is purchasing Sprout for $1 billion.
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

For public good, not for profit.

Donate